Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

Summary

GBI Research’s report, “Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma”, provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the technology that shape the industry dynamics for the key geographies: the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and analyzes the licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes -
- Annualized market data from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading technology in this space
- Analysis of the leading technology in this space
- Market characterization
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps. SHOW LESS READ MORE >

1
1 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 GBI Research Report Guidance 7
3 Market Characterization: Global Epigenetics Market 8
3.1 Disease Overview 8
3.1.1 Myelodysplastic Syndrome 8
3.1.2 Cutaneous T-cell Lymphoma 8
3.2 Epigenetic Drugs 9
3.3 The US 11
3.4 Top Five European Markets 12
3.5 Japan 14
4 In-Depth Analysis 16
4.1 Introduction 16
4.2 Vidaza (Azacitidine) 16
4.2.1 Indication 16
4.2.2 Mechanism of Action 16
4.2.3 Revenue Forecast 16
4.2.4 Key Takeaway 23
4.2.5 Market Potential 23
4.2.6 Key Takeaway 29
4.2.7 Pipeline Analysis 29
4.2.8 Key takeaway 31
4.2.9 Drug Profile 32
4.3 Dacogen (Decitabine) 33
4.3.1 Indication 33
4.3.2 Mechanism of action 33
4.3.3 Revenue Forecast 34
4.3.4 Key Takeaway 39
4.3.5 Market Potential 39
4.3.6 Key Takeaway 45
4.3.7 Pipeline Analysis 45
4.3.8 Key Takeaway 47
4.3.9 Drug Profile 48
4.4 Zolinza (Vorinostat) 49
4.4.1 Indication 49
4.4.2 Mechanism of Action 49
4.4.3 Revenue Forecast 49
4.4.4 Key Takeaway 55
4.4.5 Disease Overview 55
4.4.6 Market Potential 55
4.4.7 Key Takeaway 61
4.4.8 Pipeline Analysis 61
4.4.9 Key Takeaway 63
4.4.10 Drug Profile 63
4.5 Istodax (Romidepsin) 64
4.5.1 Indication 64
4.5.2 Disease Overview 64
4.5.3 Mechanism of Action 65
4.5.4 Market Potential 65
4.5.5 Key Takeaway 71
4.5.6 Pipeline Analysis 71
4.5.7 Clinical Studies by Phases 71
4.5.8 Clinical Studies by Indication 72
4.5.9 Key Takeaway 73
4.5.10 Drug Profile 73
5 Competitive Landscape 75
5.1 Merck & Co. 75
5.1.1 Company Overview 75
5.1.2 Business Description 75
5.1.3 SWOT 77
5.2 Celgene Corporation 77
5.2.1 Company Overview 77
5.2.2 Business Description 78
5.2.3 SWOT 79
5.3 EISAI 80
5.3.1 Company Overview 80
5.3.2 Business Description 80
5.3.3 SWOT 82
6 Epigenetic Therapeutics: Appendix 83
6.1 Market Definitions 83
6.2 Abbreviations 83
6.3 Research Methodology 84
6.3.1 Coverage 85
6.3.2 Secondary Research 85
6.3.3 Primary Research 85
6.3.4 Forecasts 86
6.3.5 Expert Panel Validation 88
6.4 Contact Us 88
6.5 Disclaimer 88
6.6 Sources 88

“Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma” report provides insights on segments where epigenetic therapies may prove to be useful. The report also details the market potential for the epigenetic therapies, Furthermore, it provides insights into the epigenetic therapeutics R&D pipeline. The report also contains comprehensive profiles of the epigenetic therapies in late-stage clinical development. The report offers insights into the US, the top five markets in Europe and Japan. The report also elucidates the current competitive landscape of the epigenetic therapeutics market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Epigenetic drugs are the chemical compounds or biologics that cause epigenetic changes resulting in modified molecular protein expressions. These drugs have the potential to trigger or suppress a protein expression process.

Currently, there are four epigenetic drugs in the market, namely Vidaza, Zolinza, Dacogen and Istodax. The sales of these drugs will account for all of the revenues of the epigenetic therapeutics market. The global epigenetic therapeutics market measured in this report comprises the sales of VIdaza, Zolinza, and Dacogen in the top seven markets of the world.

Four Epigenetics Drugs Generated Revenues of $517m in 2009

Vidaza, Dacogen, Zolinza and Istodax are the four currently approved epigenetic drugs in the market. The sales of these drugs amounted to $517m in 2009. Vidaza and Dacogen are approved for the indication Myelodysplastic Syndrome (MDS) and Zolinza and Istodax are approved for the indication Cutaneous T-cell lymphoma (CTCL). Of all the drugs, Vidaza had the largest market share in 2009, followed by Dacogen.

Vidaza and Dacogen Belong to a Class of Drugs called DNA Methyltransferase Inhibitors that Dominate the Epigenetics Market

Vidaza and Dacogen belong to a new class of drugs called DNA Methyltransferase inhibitors. These drugs cause the removal of the methyl group from the cytosine residue in the DNA and cause the repression of tumor genes. Of all the drugs, Vidaza and Dacogen are the most commonly used drugs for the treatment of MDS. They are currently employed by physicians as a second or third line of therapy.

The Epigenetic Therapies are Currently Only Approved for Blood Cancer

Epigenetic drugs are currently approved to treat MDS and CTCL, which are cancers of the blood cells. MDS is a type of blood cancer that affects the stem cells secreted in the bone marrow. CTCL affects the lymphocytes that secrete T-cells. The accumulation of the proliferated T-lymphocytes in the subcutaneous regions causes a rash-like appearance and progresses to become metastasis.

Merck & Co.
Celgene Corporation
EISAI